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Abstract
Background: Signal transducer and activator of transcription-3 (STAT3) is an oncogenic transcription factor
constitutively active and aberrantly expressed in various types of malignancies, and the expression of p-STAT3 has
been recognized as a predictor of poor survival. It remains unclear how variations in p-STAT3 expression influence
clinical outcomes in esophageal squamous cell carcinoma (ESCC).
Methods: Between 1 January 2008 and 1 November 2013, 153 advanced esophageal squamous cell carcinoma
patients (stage IV) from two cancer centers in West China were treated with paclitaxel and cisplatin. We retrospectively
analyzed the clinical outcomes of patients with ESCC and examined the correlation between p-STAT3 levels and
clinical outcomes in esophageal cancer patients.
Results: Among the 153 patients, positive p-STAT3 expression was observed in 73 of 153 (47.7 %) cases. The median
PFS for patients with positive expression of p-STAT3 and negative expression of p-STAT3 was 5.0 months and
6.9 months, respectively (P < 0.001). The median overall survival was significantly higher in patients with p-STAT3
negative tumors than in those with p-STAT3 positive tumors (9.9 vs 8.9 months, P = 0.026). Kaplan–Meier survival
analysis showed that p-STAT3 expression was statistically indicative of a poor prognosis for progression-free
survival.
Conclusions: These data showed that p-STAT3 expression was significantly associated with poor prognosis in
patients with esophageal cancer and could be used as a predictive and prognostic marker in esophageal cancer.
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Background
The incidence of esophageal adenocarcinomas predom-
inantly affecting the lower esophagus and gastroesopha-
geal junction has increased substantially in USA and the
Europe, whereas the majority of esophageal cancers
worldwide are of the squamous cell carcinoma type, the
most common histological type in China [1]. Esophageal
cancer is an aggressive upper gastrointestinal malignancy
which generally presents as a locally advanced tumor that
requires multimodal therapy, and the prognosis in patients
with esophageal cancer remains poor, with a 5-year survival
of 15–34 % [2–4]. Identification of the potential molecular
markers for predicting the treatment response and progno-
sis of esophageal cancer is very important. Currently, much
interest has been focused on the signal transducer and acti-
vator of transcription-3 (STAT3), a member of the Janus-
activated kinase/STAT signaling pathway.
STAT3 can be activated by diverse upstream kinases in-
cluding cytokine receptors and tyrosine kinases, and STAT3
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was activated in nearly 50 % of the squamous cell carcin-
oma [5]. Constitutive activation of STAT3 has been
shown in various types of malignancies, and the expres-
sion of p-STAT3 has been recognized as a predictor of
poor survival [5–8]. In esophageal cancer, however, little
is known about the prognostic relevance of p-STAT3, al-
though Chen et al. [5] showed the expression of p-STAT3
in an immunohistochemical study. We therefore investi-
gated the correlation between p-STAT3 levels and clinical
outcomes in esophageal cancer patients.
Methods
One hundred and fifty-three advanced esophageal squa-
mous cell carcinoma patients (stage IV) were treated
with paclitaxel and cisplatin between 1st January 2008
and 1st October 2013, at West China Hospital, Sichuan
University, and the Central Hospital of Enshi Tujia and
Miao Autonomous Prefecture. The main end points
were progression-free survival (PFS), overall survival
(OS), and response to chemotherapy. PFS was defined
as the lapse of time between the start of chemotherapy
and progressive disease or death. OS was defined as the
lapse of time between the start of chemotherapy and
death of any cause. The study protocol was approved
by the Institutional Review Board of Enshi Tujia and
Miao Autonomous Prefecture Central Hospital.
During treatment, all patients underwent chest CT
scan every 2–3 months as the part of clinical routine
practice. PFS and OS distributions were estimated using
the Kaplan–Meier method, and survival curves were
compared by log-rank test. Univariate and multivariate
Cox proportional hazards regression analysis was
performed to determine independent prognostic factor
for disease survival. All the parameters related to PFS
and OS (by Kaplan–Meier with a P value <0.2) were
included into the multivariate model (Cox regression).
A p value of less than 0.05 was considered statistically
significant. Data was analyzed by using the SPSS 16.0
(SPSS Inc., Chicago, Illinois) software package. Adverse
events were classified according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE) version 4.0.
Immunohistochemical staining (IHC)
Sections (3 mm thick) of formalin-fixed, paraffin-embedded
tumor specimens were heated in a microwave oven to
maintain the temperature at 92–98 °C for 10–15 min for
antigen retrieval, then incubated with 10 % normal goat
serum. The sections were first incubated with primary
purified rabbit antihuman STAT3 polyclonal antibody
(1:150, Santa Cruz Biotech, CA, USA) at 4 °C overnight,
then biotin-labeled rabbit anti-goat secondary antibody at
room temperature for 30 min. After washing with PBS
three times, streptavidin-coupled horseradish peroxidase
(streptavidin-HRP) was added and incubated at room
temperature for 20 min, followed by adding freshly pre-
pared 0.01 % diaminobenzidine with 5–10 min incubation.
The reaction was terminated by washing with distilled
water three times. Cells were counterstained with
hematoxylin–eosin and returned to blue with ammo-
nia water. After staining, the sections were dehydrated
with gradient ethanol, cleared with xylene, and then
mounted with the cover slips.
STAT3 expression level was determined by integrating
the percentage of stained cells and staining intensity
(bordering (score 1), weak (score 2), moderate (score 3),
and strong (score 4)). The extent of staining was scored
according to the percentage of positive-stained tumor
cells in the field: Score 0 was attributed to tumors with
absence of staining. The extent of staining was scored as
0 (negative), 1 (0–25 %), 2 (26–50 %), 3 (51–75 %), or 4
(76–100 %), according to the percentage of positive-
stained tumor cells in the field. The product of the inten-
sity and extent score was considered as the mean IHC
score. The staining was observed and assessed by three
independent pathologists blind to clinical data.
Results and discussion
Expression of p-STAT3 in esophageal squamous cell
carcinoma tissue
Phosphorylated-STAT3 was expressed only in the nuclei
of the tumor cells [9] (Fig. 1a, b), and our results showed
that elevated levels of p-STAT3 protein were detected in
the nuclei of 73 out of 153 total esophageal squamous
cell carcinoma cancer specimens.
Prognostic significance of p-STAT3 expression
One hundred and fifty-three advanced esophageal
squamous cell carcinoma patients started paclitaxel
(135 mg/m2) and cisplatin (75 mg/m2) as the first line
treatment between 1st January 2008 and 1st November
2013. Median follow-up time was 8.6 months (8.6 ±
3.5, range 2.6–26.7). Among the 153 patients, 80
(52.3 %) were negative, and 73 (47.7 %) were positive for
p-STAT3 expression. There were no significant correlations
between p-STAT3 expression levels and clinical characteris-
tics, including age (P = 0.605), gender (P = 0.816), differen-
tiation (P = 0.599), site of metastasis (P = 0.298), or site of
tumor (P = 0.415, Table 1). The median PFS for patients
with positive expression of p-STAT3 and negative expres-
sion of p-STAT3 was 5.0 months and 6.9 months, respect-
ively (HR 1.380, 95 % CI 0.698 to 2.062, p < 0.001, Fig. 2).
The median overall survival was significantly higher in
patients with p-STAT3-negative tumors than in those with
p-STAT3-positive tumors (9.9 vs 8.9 months, HR 1.112,
95 % CI 0.4305 to 1.794, p = 0.026, Fig. 3). Table 2 gives an
overview of all previously described prognostic factors
assessed by univariate analysis. In univariate, primary site of
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tumor, p-STAT3 expression levels, and chemotherapy
cycles were significant in univariate analysis. In multivariate
analysis (Table 3), primary site and p-STAT3 expression
levels were independently linked to PFS. Degree of differ-
entiation and primary site were an independent prognostic
factor in multivariate analysis for disease overall survival.
Response to chemotherapy in esophageal squamous cell
carcinoma
Response results are summarized in Table 4. Of the 73
patients with positive expression of p-STAT3, 9 (12.3 %)
achieved a complete response (CR), 32 (43.8 %) achieved
a partial response (PR). Seventy patients demonstrated a
stable disease (SD), which resulted in a response rate of
56.1 %. For those patients with negative p-STAT3 expres-
sion, 12 achieved a confirmed response, 36 were partial
responses, and 18 had stable disease. There were no
significant differences in RR rate between patients with
positive p-STAT3 expression and negative p-STAT3 expres-
sion (p = 0.264). Table 5 lists the adverse events and the
proportion of patients experiencing adverse events during
the treatment. The common grade 3⁄4 adverse events were
anemia, neutropenia, thrombocytopenia, vomiting, consti-
pation, anorexia, nausea, and leukocytopenia.
Discussion
The prognosis for patients with advanced esophageal
carcinoma is poor because of the limited response to
Fig. 1 IHC pictures: a. Predominantly the cytoplasmic staining of p-STAT3 in esophageal squamous cell cancer (SP method, ×100). b. p-STAT3
negative expression in esophageal squamous cell cancer (SP method, ×100)
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conventional chemotherapeutic agents. The combination
of docetaxel with cisplatin was reported in a phase II
study has a response rate of 43 % in patients with gastric
or gastroesophageal cancer. The median overall survival
time on this study of 8.9 months in patients with posi-
tive expression of pSTAT3 and 9.9 months in p-STAT3
negative group is comparable to the results in phase II
and III studies testing platinoid-based combinations
[10–12]. Nevertheless, by far, there are no efficient mo-
lecular markers to predicting the treatment response
and prognosis of esophageal cancer.
Immunoexpression of p-STAT3 has been recognized as a
predictor of poor survival in many malignancies [6, 7, 13].
Immunohistochemical data [9] showed that p-STAT3 was
significantly overexpressed in esophageal squamous cell
carcinoma (ESCC) when compared with those in normal
esophageal mucus, and overexpression of STAT3 signifi-
cantly associated with the metastasis of ESCC through
increasing the invasive ability of tumor cells. In this study,
we found that the expression of activated STAT3 (p-STAT3)
significantly correlated with a worse prognosis in patients
with this disease by univariate analysis. p-STAT3 expression
was an independent prognostic factor for progression-free
survival; it was indicated that p-STAT3 expression can be an
important factor to predict prognosis. One immunohisto-
chemical study [14] has been reported on p-STAT3 expres-
sion in esophageal carcinoma, in which the researchers
reported that 82 specimens (47.4 %) showed positive
immunoexpression of p-STAT3 in 173 esophageal cancer
specimens. Similarly, STAT3 was activated in 47.7 % of
esophageal squamous cell carcinoma in immunohisto-
chemical analysis of our study. In univariate and multi-
variate analyses, poor treatment response, no tumor
resection, and positive IL-6 staining were significantly
associated with shorter survival. However, there were no
details about whether positive STAT3 staining was associ-
ated with shorter survival in the study. Another study by
Li and co-workers [15] demonstrated that high expression
Table 1 Patient characteristics
p-STAT3+ p-STAT3− P
Age (year)
Mean 40-83 40-83 42–81 0.605
Range 58.100 58.100
Sex
Male 127.000 61.000 66 0.816
Female 26.000 12.000 14
Primary sit
Upper thorax 26.000 12.000 14
Middle thorax 46.000 22.000 24 0.415
Lower thorax 81.000 39.000 42
Degree of differentiation
Well 35.000 16.000 19
Moderate 74.000 34.000 40 0.599
Poor 44.000 23.000 21
Local/distant metastasis
Local 17.000 5.000 11 0.298
Distant 137.000 68.000 69
Site of metastasis
Lung 49.000 20.000 29
Liver 25.000 15.000 10
Lymph node 68.000 32.000 36 0.307
Lung and liver 6.000 4.000 2
Other 5.000 2.000 3
Fig. 3 Kaplan–Meier curves showing median overall survival (mOS) for
153 metastasis esophageal cancer patients treated with paclitaxel and
cisplatin according to p-STAT3 levels. The median overall survival was
significantly higher in patients with p-STAT3 negative tumors than in
those with p-STAT3-positive tumors (9.9 vs 8.9 months, HR 1.112, 95 %
CI 0.4305 to 1.794, p = 0.026)
Fig. 2 Kaplan–Meier curves showing median progress free survival
(mPFS) for 153 metastasis esophageal cancer patients treated with
paclitaxel and cisplatin according to p-STAT3 levels. The median PFS
for patients with positive expression of p-STAT3 and negative
expression of p-STAT3 was 5.0 months and 6.9 months, respectively
(HR 1.380, 95 % CI 0.698 to 2.062, p < 0.001)
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of STAT3 was detected in 54 out of 82 TMA cancer tis-
sues (65.9 %) while most of the adjacent non-cancerous
tissues showed low expression of STAT3. More import-
antly, high expression of STAT3 was found to have a
highly significant relationship with advanced tumor stage
(P = 0.047) and poor prognosis (P = 0.023). The median
overall survival time was 27.67 months in patients with
low expression of STAT3 compared with 17.48 months in
patients with high expression of STAT3 (P = 0.044). Simi-
larly, in our study, we determined that high expression of
STAT3 significantly correlated with poor prognosis. The
median overall survival was significantly higher in patients
with pSTAT3-negative tumors than in those with p-
STAT3-positive tumors (9.9 vs 8.9 months, HR 1.112,
95 % CI 0.4305 to 1.794, p = 0.026, Fig. 3). However, we
found the median overall time in our study was obviously
shorter than that in Li’s study. We thought the cause
might be the tumor stages, of 82 patients, 28 (34.1 %) had
a stage I + II diagnosed at surgery in Li’s study.
STAT proteins are a family of latent cytoplasmic tran-
scription factors and contribute to the progression of
malignant transformation [16]. The STAT family of tran-
scription factors is involved in several cellular processes,
such as proliferation, survival, apoptosis, and differenti-
ation [17, 18]. STAT3 protein was overexpressed and
persistently activated appears to play a role in the cell
transformation and tumor progression by stimulating
cell growth, promoting tumor angiogenesis, mediating
immune evasion, and conferring resistance to apoptosis
induced by chemotherapeutic agents [19–21]. Although
our result indicated that the activation of STAT3 contrib-
uted to a poor prognosis, the mechanism of constitutive
activation of STAT3 has not been clarified well in esopha-
geal squamous cell carcinoma. It is reported that STAT3
activated by diverse receptor and non-receptor tyrosine
kinases, including, platelet-derived growth factor receptor,
Table 4 Reponses to chemotherapy in the two group cases (%)
GROUP RR CR PR SD PD
p-STAT3+ 41 (56.1 %) 9 (12.3 %) 32 (43.8 %) 17 (22.5) 15 (20.6 %)
p-STAT3− 52 (65.0 %) 12 (15 %) 36 (45.0 %) 18 (23.8) 14 (17.5 %)
P value 0.264 0.632 0.491 0.885 0.631
Table 3 multivariate analysis
For PFS P value Hazard ratio 95 % CI
Age 0.947 1.014 0.674–1.524
Chemotherapy cycles 0.531 1.063 0.879–1.285
Primary site 0.001 1.839 1.296–2.610
Degree of differentiation 0.809 1.031 0.808–1.315
Local/distant metastasis 0.478 1.238 0.687–2.229
p-STAT3 expression levels 0.009 0.554 0.356–0.862
For OS P value Hazard ratio 95 % CI
Age 0.810 0.899 0.598–1.352
Chemotherapy cycles 0.899 1.012 0.844–1.212
Primary site 0.050 1.431 0.999–2.049
Degree of differentiation 0.041 0.761 0.586–0.990
Local/distant metastasis 0.302 1.380 0.748–2.543
p-STAT3 expression levels 0.161 0.732 0.473–1.132
Table 2 Univariate analysis
Patient characteristics PFS p OS p
Age (years)
v < 60 6.2 0.08 9.5 0.929
≥ 60 5.8 9.1
Sex
Female 5.3 0.584 9 0.949
Male 6.2 9.4
Degree of differentiation




Upper thorax 7.3 0.001 9.2 0.038
Middle thorax 6.7 10.3
Lower thorax 3.8 8.9
Chemotherapy cycles
1 6.1 0.145 8 0.038
2 5.6 8.2
3 6.4 9.2
≥ 4 6.7 10.5
Metastasis
Local 6.9 0.0587 9.5 0.714
Distant 5.9 9.2
Table 5 Events in the two groups (cases %)
Item All grades Grade 3⁄ 4
p-STAT3+ p-STAT3− p-STAT3+ p-STAT3−
Leukocytopenia 49 (67.1 %) 60 (75 %) 7 (9.6 %) 8 (10 %)
Neutropenia 60 (82.2 %) 63 (78.7) 13 (17.8 %) 15 (18.8 %)
Hemoglobin 44 (60.3 %) 49 (61.2 %) 22 (30.1 %) 20 (25 %)
Thrombocytopenia 13 (16.3 %) 14 (17.5 %) 10 (13.7 %) 10 (12.5 %)
Nausea 7 (9.6 %) 9 (11.2 %) 8 (11 %) 9 (11.25 %)
Vomiting 13 (16.3 %) 15 (18.6 %) 12 (16.4 %) 13 (16.25 %)
Anorexia 14 (19.2) 11 (13.8 %) 9 (12.3 %) 9 (11.25 %)
Diarrhea 1 (1.4 %) 1 (1.3 %) 0 0
Constipation 16 (21.9 %) 19 (23.8 %) 10 (13.7 %) 15 (18.8)
Fatigue 31 (42.5 %) 30 (37.5) 3 (4.1 %) 5 (6.3 %)
Liver dysfunction 14 (19.1 %) 17 (21.3 %) 4 (5.5 %) 6 (7.5 %)
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EGFR, Janus-activated kinases (JAK), and src in other
malignancies [22]. STAT3 is an important mediator of the
oncogenic effects of EGF and transforming growth factor
in squamous cell carcinoma of the head and neck and
non-small lung cancer [22]. Chen et al. [5] showed that
apoptosis had been induced by the inhibition of STAT3 with
a small molecular inhibitor of the Janus-activated kinase/
STAT pathway in cervical cancer. Chen W et al. [23] dem-
onstrated that addition of a STAT3 inhibitor, NSC-74859, to
a standard regimen of cetuximab can increase the suscepti-
bility of hepatoma cell lines to cetuximab. It is reported that
combined inhibition of EGFR and STAT3 by erlotinib and
niclosamide more effectively induced apoptosis in tumor
tissues without toxicity for normal tissues [24]. STAT3
signaling pathways play a pivotal role in oncogenesis, and
thus targeting the STAT signaling pathway appears to be an
effective anticancer treatment strategy.
In summary, our results demonstrated that p-STAT3
expression in esophageal cancer acts as a predictor of
poor prognosis. STAT3 appears to be one of the onco-
genic pathways activated in human esophageal cancers.
The constitutive STAT3 signaling may be a novel thera-
peutic target for esophageal cancers.
Conclusions
These data showed that p-STAT3 expression was signifi-
cantly associated with poor prognosis in patients with
esophageal cancer, and could be used as a predictive and
prognostic marker in esophageal cancer.
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